These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 5755238)

  • 1. [Intravenous administration of ornithine aspartate to patients with hepatic diseases].
    Schäfer W
    Munch Med Wochenschr; 1968 Oct; 110(43):2521-5. PubMed ID: 5755238
    [No Abstract]   [Full Text] [Related]  

  • 2. [On the therapy of liver diseases with ornithine aspartate].
    Melzer H; Weber D; Wotzka R
    Med Klin; 1969; 64(35):1541-4. PubMed ID: 5354488
    [No Abstract]   [Full Text] [Related]  

  • 3. [Amino acids prevent hepatic encephalopathy. Ornithine-aspartate in hyperammonemia--results of a study].
    Hartung HD
    Fortschr Med; 1989 Mar; 107(8):56. PubMed ID: 2651255
    [No Abstract]   [Full Text] [Related]  

  • 4. [Confirmation of a liver-protecting action of L-ornithine-L-aspartate using the experimental model of hypokalaemic liver damage].
    Raab W
    Wien Klin Wochenschr; 1972 May; 84(21):348-9. PubMed ID: 5031515
    [No Abstract]   [Full Text] [Related]  

  • 5. [Influence of ornithine aspartate on the experimentally induced hyperammoniemia. Clinico-experimental study].
    Henglein-Ottermann D
    Ther Ggw; 1976 Sep; 115(9):1504-18. PubMed ID: 968783
    [No Abstract]   [Full Text] [Related]  

  • 6. [Our clinical experience with ornithine aspartate].
    Szirmai E
    Minerva Med; 1971 Jun; 62(47):2376-82. PubMed ID: 5087700
    [No Abstract]   [Full Text] [Related]  

  • 7. [Betaine aspartate in the therapy of liver diseases].
    Cairella M; Volpari B
    Clin Ter; 1972 Mar; 60(6):513-34. PubMed ID: 5038777
    [No Abstract]   [Full Text] [Related]  

  • 8. [Further clinical experiences with ornithine aspartate in liver diseases].
    Wotzka R; Weber D
    Ther Ggw; 1972 Mar; 111(3):400-12. PubMed ID: 5024593
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experiences with ornithine-aspartate in liver diseases].
    Aschke J
    Med Welt; 1969 Mar; 12():657-62. PubMed ID: 5767441
    [No Abstract]   [Full Text] [Related]  

  • 10. [Personal experiences in the treatment of internal diseases with ornithine aspartate].
    Perinović M; Robović Z; Grujić M; Ljubojević S
    Med Arh; 1969; 23(3):29-32. PubMed ID: 5200044
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapy of experimental and clinical hyperammonaemia with ornithine-alpha-ketoglutarate].
    Szám I; Szentner J; Hegedüs-Wein I; Vass A; Szilárd T
    Wien Med Wochenschr; 1974 May; 124(20):319-25. PubMed ID: 4829691
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical experiences in liver diseases (specially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate].
    Hunold W
    Z Allgemeinmed; 1973 Apr; 49(10):469-72. PubMed ID: 4580434
    [No Abstract]   [Full Text] [Related]  

  • 13. [Protection of the liver and liver therapy with Hepamerz].
    Heynen U
    Z Allgemeinmed; 1970 Jan; 46(2):87-8. PubMed ID: 5439291
    [No Abstract]   [Full Text] [Related]  

  • 14. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
    Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
    J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
    Chen MF; Li RC; Chen CH; Gao XC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment of hyperazotemia in liver cirrhosis].
    Loginov AS; Blok IuE
    Ter Arkh; 1983; 55(9):126-31. PubMed ID: 6635969
    [No Abstract]   [Full Text] [Related]  

  • 17. A controlled clinical trial of lactulose in hepatic encephalopathy.
    Simmons F; Goldstein H; Boyle JD
    Gastroenterology; 1970 Dec; 59(6):827-32. PubMed ID: 4922276
    [No Abstract]   [Full Text] [Related]  

  • 18. [Parenteral magnesium treatment in chronic liver diseases].
    Merker G; Selisko O
    Z Gesamte Inn Med; 1967 Mar; 22(6):182-5. PubMed ID: 5593100
    [No Abstract]   [Full Text] [Related]  

  • 19. [Ornithine aspartate in hepatic encephalopathy: an established new therapeutic approach. Overview and results of current randomized studies].
    Krüger B; Held C; Kircheis G
    Z Arztl Fortbild (Jena); 1994 Sep; 88(9):673-9. PubMed ID: 7975752
    [No Abstract]   [Full Text] [Related]  

  • 20. [Action of the essentiale preparation-an injectable solution-on the syndrome of persistent hepatic cytolysis].
    Brauner F; Cercel I; Duda R; Zilberman L; Roman D
    Rev Med Chir Soc Med Nat Iasi; 1974; 78(3):707-9. PubMed ID: 4453700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.